Study on Immunomodulating Effects of Del-Immune V

STUDY OF INTERFERONOGENOUS ACTIVITY OF THE NEW PROBIOTIC FORMULATION DEL-IMMUNE V®

“The biochemical structure of Del-Immune V and preliminary experimental and clinical data indicate that Del-Immune V may be highly effective in infectious diseases of viral (flu, hepatitis C), bacterial (bronchitis), and fungal etiology, allergies of all severity levels, asthma, chronic fatigue, and fibromyalgia.1-6 The mechanism of such a wide scope of biological activity of the formulation is still unclear. The goal of our research, therefore, was to study the mechanisms of the immunomodulating effects of Del-Immune V and to describe its dose-dependent effects on production of immunoregulatory cytokines in vivo and in vitro.

“The last 5 years have been marked by increasingly active study of the mechanisms of theimmunobiological effects of probiotics and bacterial medications.7-16 As a result, bacterial medications such as liastenum (blasten), deodan, licopid, prodigiosanum, salmosanum, sodium nucleinate, MC (molecular composition – yeast DNA and Tilorone), biostim, BCG, rumurtide, ribomunyl, and lactolin are being used, in both trials and clinical practice, for different pathologies.1-4 The adjuvant effect of BCG and the immunomodulating activity of formulations containing derivatives of lactobacilli, such as liastenum (blasten, Lactobacillus delbrueckii) and deodan (Lactobacillus bulgaricus), have been associated with peptidoglycans and their structural components, muramyl dipeptides (MDP). The most active analog of MDP, MurNac-L-Ala-D-Glu-NH2, has demonstrated adjuvant and pleiotropic effects and is capable of inducing a number of cytokines: IL-1, tumor necrosis factor (TNF- α), IL-2, IL-6, IL-8, IL-12, and interferon gamma (IFN-γ).17-26 These cytokines in turn stimulate nonspecific cytotoxicity of normal and effector lymphocytes and natural killer cells (NK), and coordinate the body’s immune response, depending on the nature of the aggressive agent and the T-helper differentiation (Th1 or Th2).9-12

Read the full text in .PDF format here: STUDY OF INTERFERONOGENOUS ACTIVITY OF THE NEW PROBIOTIC FORMULATION DEL-IMMUNE V®

REFERENCES
1. Karsonova MI, Andronova TM, Pinegin BV, Khaitov RM. Immunostimulating activity of muramyl dipeptide and its derivatives. Journal of
    Microbiology, Moscow. 1999;3:104-110. (in Russian)
2. Vospyakov VG, Petrov LN, Kalinin IM, Grishnyakov SB, Rugal VI, Kravets VN, Gonchar VA, Mosienko VS, Shynkarenko LN. Glycopeptides
    from lactobacilli as regulators of hemopoiesis and immunity. HIV/AIDS and Related Problems. 2000;4(1):32. (in Russian)
3. Voloska O, Shynkarenko L, Todosiychuk T, Zarutska I, Zabolotna D. Selection of the excipients for ready-made clinic formulations based on
    the selection lactic acid bacilli strains. Odessa Medical Journal. 2006,5(97), pp.3-6, (in Ukrainian)
4. Shynkarenko L, Richy E, Zabolotny D, Dechtyarenko N, Sichel J. Medical experiences of using Del-Immune – lysate powder of probiotic
    cells for immediate immune system support. In Abstracts of International Congress “Probiotics, Prebiotics, Synbiotics and Functional Food:
    Scientific and Clinical       Aspects.” May 15-16, 2007; St.Petersburg, Russia, #270, p.A76.
5. Tymoshok N, Shynkarenko L, Sichel J, Pidgorskyy V, Spivak M. Probiotic formulation Del-Immune V in experimental herpetic infection in
    mice. Abstracts V International Conference “Bioresourses and viruses.” September 10-13, 2007; Fitosociocenter, Kiev, Ukraine, p.22.
6. Spivak NY, Pidgorskyy V, Timoshok N, Lasarenko L, Shynkarenko-Sichel L. Immune regulatory cytokines Del-Immune V® induction and its
    impact on cytotoxicity of natural killer cells. II European Conference on Probiotics and their Applications, Cracow, Oct.15-17, 2008.
    Conference publication, p. 21.
7. Shirinskii VS, Zhuk EA. Characteristics and clinical use of immunostimulants. Ter.Arkh.1990;62(12):125-32.
8. Mosienko VS, Mosienko MD, Savtsova ZD, et al. Blasten – new domestic immunomodulator of the biological origin. Magazine AMS
    Ukraine. 1999;5(1):79-86.
9. Drannik GM, Mosienko VS. Blasten – stimulator of production IL-1 on patients with chronic obstructive bronchitis. Galytsky Medical News.
    1998;5(3):34-42.
10. Timoshok NO. Antibacterial activity of interferon inductors of different origin. PhD Dissertation reference. 03.00.07.Microbiology. ?,
    2002;1-22.
11. Lammers KM, Brigidi P, Vitali B, et al. Immunomodulatory effects of probiotic bacteria DNA: IL-1 and IL-10 response in human peripheral
    blood mononuclear cells. FEMS Immunol Med Microbiol. 2003;38(2):165-72.
12. Kaliuzhin OV. Muramil peptide’s derivates in experiment and in clinic. Journal of Microbiology (Russia), 1998;1:104-8.
13. Bondarenko VM, Ubakova EI, Lavrova VA. Immunostimulating action of lactobacteria used as the basis of probiotic preparations. Zh
    Mikrobiol Epidemiol Immunobiol. 1998;5:107-12.
14. Erickson KL, Hubbard NE. Probiotic immunomodulation in health and disease. J Nutr. 2000;130(2S-Suppl):403S-9S.
15. Solis Pereyra B, Lemonnier D. Induction of human cytokines by bacteria used in dairy foods. Nutr Research. 1993;13:1127-40.
16. Iliev ID, Kitazawa H, Shimosato T, et al. Strong immunostimulation in murine immune cells by Lactobacillus rhamnosus GG DNA containing
     novel oligodeoxynucleotide pattern. Cell Microbiol. 2005;7930;403-414.
17. Drannik GI, Svidro OV, Kushko LJ, Mosienko VS. Clinical and immunological efficiency of blasten used in patients with bronchopulmonary
     pathology. Problems of Ecology and Medicine. 1998, vol.2, #1-2, pp.13-17. (in Russian)
18. Mosienko VS, Mosienko MD, Savtsova ZD, Danilenko VS, Volkova MU, Shynkarenko LN, Shcheglova NA, Vospyakov VG, Svidro OV, Menyok
    TA. Blasten— new domestic immunomodulator of the biological origin. Magazin of AMS of Ukraine.1999, vol.5, #1, pp.79-86. (in Ukrainian)
19. Zaykov SV, Shpilevaya SI. Prospects of the application of the immunomodulators of muramyl peptides line in oncology. Rational
    Pharmacology, 2007;3(04):56-59.
20. Zaykov SV, Plicanchuk OV. The dynamics of immunologic induced in patients with first diagnosed destructive lung tuberculosis using
    immunomodulator of muramyl peptide series. Tavricheskiy medico-biology news, vol.12, #1, pp.62-66.
21. Ellouz F, Adam A, Ciorbaru R, Lederer E. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives.
    Biocemical and Biophysical Research Communications. 1974;59(4):1317-1325.
22. Allison AC, Byars NE. An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated
    immunity. J.Immunol Methods. 1986;95(2):157-168.
23. Imeri L,Bianchi S, Mancia M. Mutamyl dipeptide and IL-1 effects on sleep and brain temperature after inhibition of serotonin synthesis.
    Am J Physiol Regul Integr Comp Physiol 1997;273:R1663-1668.
24. Yoshimura A, Lien E, Ingalls RR, Tuomanen E, Dziarski R, Golenbock D. Cutting Edge: Recognition of Gram-Positive Bacterial Cell Wall
    Components by the Innate Immune System Occurs Via Toll-Like Receptor2 .The Journal of Immunology. 1999;163:1-5.
25. Matricardi PM, Bjorksten B, Bonini S, Bousquet J, Djukanovic R, Dreborg S, Gereda J, Malling H-J, Popov T, Raz E, Renz H. Microbial
    products in allergy prevention and therapy. Allergy, 2003; 58:461-471.
26. Galdeano CM, de LeBlanc AM, Vinderola G, Bonet ME, Perdogon G. Proposed model: mechanisms of immunomodulation induced by
    probiotic bacteria. Clinical and Vaccine Immunology. May 2007:485-492.

Leave a Reply